BRPI0611250A2 - composto, enanciÈmeros, diastereoisÈmeros do mesmo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto - Google Patents

composto, enanciÈmeros, diastereoisÈmeros do mesmo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto Download PDF

Info

Publication number
BRPI0611250A2
BRPI0611250A2 BRPI0611250-1A BRPI0611250A BRPI0611250A2 BR PI0611250 A2 BRPI0611250 A2 BR PI0611250A2 BR PI0611250 A BRPI0611250 A BR PI0611250A BR PI0611250 A2 BRPI0611250 A2 BR PI0611250A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
compound according
compounds
formula
Prior art date
Application number
BRPI0611250-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Arwinder Nagi
Shamin Hasan
Zafar Ali
Ramarao Chatlapalli
Mohamed Ghorab
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37432377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0611250(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0611250A2 publication Critical patent/BRPI0611250A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
BRPI0611250-1A 2005-06-09 2006-06-07 composto, enanciÈmeros, diastereoisÈmeros do mesmo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto BRPI0611250A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68880605P 2005-06-09 2005-06-09
US60/688,806 2005-06-09
PCT/US2006/022150 WO2006135638A2 (en) 2005-06-09 2006-06-07 Tanaproget compositions containing ethinyl estradiol

Publications (1)

Publication Number Publication Date
BRPI0611250A2 true BRPI0611250A2 (pt) 2011-02-15

Family

ID=37432377

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0611250-1A BRPI0611250A2 (pt) 2005-06-09 2006-06-07 composto, enanciÈmeros, diastereoisÈmeros do mesmo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto

Country Status (13)

Country Link
US (3) US20060280800A1 (https=)
EP (1) EP1893217A2 (https=)
JP (1) JP5339903B2 (https=)
CN (2) CN103989687A (https=)
AR (1) AR057060A1 (https=)
AU (1) AU2006258048A1 (https=)
BR (1) BRPI0611250A2 (https=)
CA (1) CA2610767C (https=)
HN (1) HN2006020928A (https=)
MX (1) MX2007015571A (https=)
PE (1) PE20070001A1 (https=)
TW (1) TW200716137A (https=)
WO (1) WO2006135638A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG120970A1 (en) * 1999-05-04 2006-04-26 Ligand Pharm Inc Cyclothiocarbamate derivatives as progesterone receptor modulators
MX2007013467A (es) * 2005-04-28 2008-01-21 Wyeth Corp Tanaproget micronizado y composiciones que contienen el mismo.
CN101166521A (zh) 2005-04-28 2008-04-23 惠氏公司 通过湿制粒法制备包含微粒化他那普戈特的组合物
CN101166736B (zh) * 2005-04-28 2013-02-06 惠氏公司 他那普戈特的多晶型ⅱ
CN101166532B (zh) * 2005-04-28 2011-06-22 惠氏公司 微粒化的他那普戈特、组合物及其制备方法
CA2610767C (en) 2005-06-09 2014-09-23 Wyeth Tanaproget compositions containing ethinyl estradiol
BRPI0819571A2 (pt) 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
SG11201401583YA (en) * 2011-10-17 2014-09-26 Lexicon Pharmaceuticals Inc Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20140006315A1 (en) * 2012-07-02 2014-01-02 Stèphane Etheve Method of marketing oregano capsules containing thymoquinone
US9326997B2 (en) 2012-09-24 2016-05-03 Ahlam E. Elakkad Composition and method for treation Oligoovulation, Oligomenorrhea and Amenorrhea
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014159377A1 (en) * 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG120970A1 (en) * 1999-05-04 2006-04-26 Ligand Pharm Inc Cyclothiocarbamate derivatives as progesterone receptor modulators
US6423699B1 (en) * 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP2005535628A (ja) 2002-06-25 2005-11-24 ワイス Ｐｒモジュレーターとしてのシクロチオカルバメート誘導体
CN1662241A (zh) * 2002-06-25 2005-08-31 惠氏公司 环硫代氨基甲酸酯衍生物在治疗与激素有关的病症中的用途
US20060009428A1 (en) 2004-07-07 2006-01-12 Wyeth Cyclic progestin regimens and kits
MX2007001812A (es) * 2004-08-13 2007-03-26 Wyeth Corp Derivados de tanaproget, metabolitos, y usos de los mismos.
CN101166532B (zh) 2005-04-28 2011-06-22 惠氏公司 微粒化的他那普戈特、组合物及其制备方法
CN101166736B (zh) 2005-04-28 2013-02-06 惠氏公司 他那普戈特的多晶型ⅱ
AU2006241189B2 (en) 2005-04-28 2012-01-19 Wyeth Llc Purified form of tanaproget
CN101166521A (zh) 2005-04-28 2008-04-23 惠氏公司 通过湿制粒法制备包含微粒化他那普戈特的组合物
MX2007013467A (es) 2005-04-28 2008-01-21 Wyeth Corp Tanaproget micronizado y composiciones que contienen el mismo.
CA2610767C (en) 2005-06-09 2014-09-23 Wyeth Tanaproget compositions containing ethinyl estradiol

Also Published As

Publication number Publication date
MX2007015571A (es) 2008-03-06
PE20070001A1 (es) 2007-01-29
AR057060A1 (es) 2007-11-14
US20120114748A1 (en) 2012-05-10
US20140194398A1 (en) 2014-07-10
JP5339903B2 (ja) 2013-11-13
EP1893217A2 (en) 2008-03-05
CN103989687A (zh) 2014-08-20
TW200716137A (en) 2007-05-01
HN2006020928A (es) 2011-02-16
AU2006258048A1 (en) 2006-12-21
US20060280800A1 (en) 2006-12-14
WO2006135638A3 (en) 2007-03-15
CN101193639A (zh) 2008-06-04
US8664208B2 (en) 2014-03-04
CA2610767C (en) 2014-09-23
WO2006135638A2 (en) 2006-12-21
CA2610767A1 (en) 2006-12-21
JP2008543758A (ja) 2008-12-04

Similar Documents

Publication Publication Date Title
BRPI0611250A2 (pt) composto, enanciÈmeros, diastereoisÈmeros do mesmo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
BRPI0611243A2 (pt) composto, enanciâmeros, diastereoisâmeros do mesmo ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
EP4129986B1 (en) Substituted pyridazine compound
JP7754865B2 (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
WO2022188729A1 (en) Fused ring derivatives useful as kras g12d inhibitors
ES2944573T3 (es) Antagonistas de TLR7/8 y usos de los mismos
WO2022143845A1 (zh) 含氮桥杂环化合物、其制备方法及其在医药上的应用
IL299071A (en) Antiviral compounds containing nitrile
EP3401314A1 (en) Covalent inhibitors of kras g12c
KR102890853B1 (ko) 갈렉틴-3의 소분자 억제제
EP3897848B1 (en) Cancer treatments
BRPI0709608A2 (pt) derivado de quinolona ou sal farmaceuticamente aceitável deste
US9346827B2 (en) 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
JP2023539986A (ja) 呼吸器合胞体ウイルス感染症の治療に有用なベンゾジアゼピン誘導体
JP2020502160A (ja) Ｎｒｆ２アクチベーター
CA2976369A1 (en) Biaryltriazole inhibitors of macrophage migration inhibitory factor
JP2019031449A (ja) スルホンアミド誘導体及びそれを含有する医薬組成物
US20210163443A1 (en) Febrifugine Derivatives
WO2008125210A1 (en) Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases
WO2024213044A1 (en) Azacyclo-carbonyl-fused ring derivatives and use thereof
CA3210102A1 (en) Diazepine derivatives useful in the treatment of clostridium difficile
ES2359935T3 (es) Derivados de 2,6-quinolinilo, procedimientos para prepararlos y su uso como medicamento.
WO2008125215A1 (en) Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
CN101193883A (zh) 2，6喹啉基衍生物、其制备工艺以及其作为药物的用途
WO2025215286A1 (en) Sulfonamides, compositions comprising said sulfonamides, methods for the preparation of said sulfonamides, and said sulfonamides for use as medicament and in a method for the treatment or prevention of an ocular disease or condition, or idiopathic intracranial hypertension

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B25D Requested change of name of applicant approved

Owner name: WYETH LLC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.